Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

CV Therapeutics reports phase I proof-of-concept data for CVT-3619

March 6, 2009

Enobia completes enrollment in clinical trial of ENB-0040 in infantile hypophosphatasia

March 5, 2009

New SCD inhibitors for obesity imparted in recent GSK patent

March 5, 2009

KV Pharmaceutical restructures company to focus on promotion of Acrux's Evamist

March 4, 2009

Depomed completes enrollment in phase III clinical trial of DM-5689

March 4, 2009

Amicus suspends enrollment for phase II AT-2220 trial in Pompe disease

March 3, 2009

Autoantigen insulin vaccine shows potential in newly diagnosed type 1 diabetes mellitus

March 3, 2009

MannKind updates NDA submission status for Afresa

March 2, 2009

Indeglitazar, a pan-agonist of PPARs, entering phase II trial for type 2 diabetes mellitus

March 2, 2009

DeveloGen reports positive phase I results for DG-3173

Feb. 27, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 21, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...